EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
06/30/2021
EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
|
|
06/15/2021
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
June 14, 2021 08:03 AM Eastern Daylight Time | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
|
|
06/04/2021
Alkermes’s disappointment hones melanoma niche focus
June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
|
|
06/04/2021
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
June 04, 2021 09:08 ET | Source: Iovance Biotherapeutics, Inc. 86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune…
|
05/28/2021
How Tennis Star Naomi Osaka is Helping People of Color Protect Their Skin
We’re proud to partner with Mediaplanet on the recently published Skin Health campaign, out today! Skin diseases affect as many…
|
05/21/2021
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
|
|
04/15/2021
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
|
|
04/14/2021
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
|
|
03/11/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
March 11, 2021 | Source: PRNewswire DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
|
|
02/05/2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
|
|
Recent Posts
Apr. 16, 2024
Navigating the Journey Together – Conversations with Melanoma Caregivers
Apr. 12, 2024
May is Brain Tumor Awareness Month
Apr. 11, 2024
President’s Letter | April 2024
Apr. 11, 2024
Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk
Apr. 11, 2024